Global Frequency, Diagnosis, and Treatment of Hereditary Angioedema with Normal C1 Inhibitor
Interplay of On-demand Trials for Hereditary Angioedema Attacks and Treatment Guidelines
Indirect Treatment Comparison of Oral Sebetralstat and Intravenous Recombinant Human C1 Esterase Inhibitor for On-demand Treatment of Hereditary Angioedema Attacks
On-demand Treatment of Hereditary Angioedema Attacks: Patient-reported Utilization, Barriers, and Outcomes
Advent of Oral Medications for the Treatment of Hereditary Angioedema
Closing Gaps in Hereditary Angioedema Management: Addressing Delays in On-demand Treatment
Oral Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks
The Complexities of Decision-Making Associated with On-Demand Treatment of Hereditary Angioedema (HAE) Attacks
Sebetralstat: A Rapidly Acting Plasma Kallikrein Inhibitor for the On-demand Treatment of Hereditary Angioedema
Real-world Reporting Rates of Administration-site Reactions with On-demand Treatment of Hereditary Angioedema Attacks
Oral Factor XIIa Inhibitor KV998086 Suppresses FXIIa and Single Chain FXII Mediated Kallikrein Kinin System Activation
Evaluation of Patient-reported Outcome Measures for On-demand Treatment of Hereditary Angioedema Attacks and Design of KONFIDENT, a Phase 3 trial of Sebetralstat
Hereditary Angioedema with Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns
Titanium is a Potent Inducer of Contact Activation: Implications for Intravascular Devices
An Investigational Oral Plasma Kallikrein Inhibitor for On-demand Treatment of Hereditary Angioedema: A Two-part, Randomized, Double-blind, Placebo-controlled, Crossover Phase 2 Trial
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential On-demand Treatment for Hereditary Angioedema
Pharmacological Suppression of the Kallikrein Kinin System with KVD900: An Orally Available Plasma Kallikrein Inhibitor for the On-demand Treatment of Hereditary Angioedema
Absorption, Metabolism and Excretion of Sebetralstat (KVD900) Following a Single Oral Dose in Healthy Male Participants
KVD900, An Oral On-demand Treatment for Hereditary Angioedema; Phase 1 Study Results
A Mechanism for Hereditary Angioedema Caused by a Lysine 311-to-glutamic Acid Substitution in Plasminogen
Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats
Polyphosphate Expression by Cancer Cell Extracellular Vesicles Mediates Binding of Factor XII and Contact Activation
One-time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-involved Diabetic Macular Edema and Reduced Vision: An Open-label Phase 1B Study
Plasma Kallikrein Mediates Brain Hemorrhage and Edema Caused by Tissue Plasminogen Activator Therapy in Mice After Stroke
